key: cord-1054582-fxu172ml
authors: Abdallah, Sara J.; Voduc, Nha; Corrales-Medina, Vicente F.; McGuinty, Michaeline; Pratt, Alexandre; Chopra, Anchal; Law, Angeline; Garuba, Habibat A.; Thavorn, Kednapa; Reid, Ryan E. R.; Lavoie, Kim L.; Crawley, Angela; Chirinos, Julio A.; Cowan, Juthaporn
title: Symptoms, Pulmonary Function, and Functional Capacity Four Months after COVID-19
date: 2021-03-30
journal: Annals of the American Thoracic Society
DOI: 10.1513/annalsats.202012-1489rl
sha: 5b943cc1ab278f417396448da997bf6fd1af8468
doc_id: 1054582
cord_uid: fxu172ml

nan

Between June and October 2020, 91 patients were screened for eligibility at The Ottawa Hospital. Of these, 15 refused participation and 13 did not meet the inclusion criteria. At the end, 25 hospitalized and 38 nonhospitalized patients were enrolled. The time to follow up was 119.9 6 16.2 days after the first positive SARS-CoV-2 test result for hospitalized patients and 129.8 6 16.5 days for nonhospitalized patients. Hospitalized patients were older and had a higher prevalence of comorbid conditions (Table 1) .

In both groups, fatigue (hospitalized, 92.0%; nonhospitalized, 97.4%) and exertional breathlessness (hospitalized, 76.0%; nonhospitalized, 81.6%) were frequently reported during the acute phase of COVID-19. At follow up, fatigue (hospitalized, 72.0%; nonhospitalized, 71.1%) and exertional breathlessness (hospitalized, 68.0%; nonhospitalized, 55.3%) persisted as two of the most frequently reported symptoms (Table 1) .

Forced vital capacity, total lung capacity (TLC), and the diffusing lung capacity for carbon monoxide (DL CO ) were lower in hospitalized patients. Subnormal TLC and DL CO were more prevalent in hospitalized patients. Left ventricular ejection fraction was similar between groups ( Table 2) .

Peak oxygen consumption ( _ VO 2 ) % predicted was lower in hospitalized versus nonhospitalized patients (hospitalized, 64.3 6 19.2%; nonhospitalized, 83.5 6 17.9%). Indices of respiratory mechanics, including inspiratory capacity and inspiratory reserve volume, were lower for a given _ VO 2 in hospitalized patients (Table 2, Figure 1 ). Peak heart rate, heart rate reserve, and oxygen pulse were lower, and the ventilatory equivalent for carbon dioxide nadir was higher in hospitalized patients. CI was identified in 68.0% of hospitalized and 18.4% of nonhospitalized patients (Table 2) . CI could not be explained by medication use alone, as only 35.0% and 0.0% of hospitalized and nonhospitalized patients with CI, respectively, were receiving heart rate-modifying treatment. Breathlessness and leg discomfort ratings were higher for a given _ VO 2 in hospitalized patients but were not different between groups at end-exercise (Table 2, Figure 1 ). Leg discomfort was the most frequently reported locus of symptom limitation to exercise in both groups, although it occurred at a lower peak _ VO 2 in hospitalized versus nonhospitalized patients ( Table 2 ).

Consistent with previous studies, we found that hospitalized and nonhospitalized survivors of COVID-19 report persistent fatigue and exertional breathlessness and exhibit impaired lung function and diminished functional capacity 3-4 months after SARS-CoV-2 infection (1-6). Although cardiopulmonary abnormalities were observed in both groups, they were more prevalent and severe in hospitalized patients.

Nonresolving lung parenchymal or pulmonary vascular lesions from the time of the acute infection (4) may account for the higher rate and severity of pulmonary sequelae in hospitalized patients. Persistent breathlessness in hospitalized patients may partly be explained by the residual impairments in TLC and DL CO . Although these findings are consistent with studies that evaluated breathlessness in patients with similar lung function defects (12) , we cannot rule out the confounding effects of age, obesity, and comorbid conditions on lung mechanics, which may explain some of the differences between groups. Furthermore, extrapulmonary factors likely also contributed to breathlessness during exercise, as both groups reported severe breathlessness (Borg . 6) at end-exercise despite the presence of a ventilatory reserve.

Cardiorespiratory fitness is a powerful predictor of mortality in the general population (13) . It is therefore striking that .50% of our COVID-19 survivors had a peak _ VO 2 below 85% predicted, a rate that is comparable to patients recovered from severe acute respiratory syndrome (14) . The respiratory quotient .1.05 in conjunction with a _ VCO 2 = carbon dioxide production; _ VE = minute ventilation; _ VO 2 = oxygen consumption. Values are n (%) or mean 6 standard deviation. *P , 0.01. † P , 0.05. ‡ P , 0.001. § n = 24, one patient was unable to perform DL CO . k n = 24, one patient did not complete transthoracic echocardiography.

ventilatory reserve at peak exercise suggests that cardiovascular factors were the primary cause of exercise limitation in both groups. Impaired tissue perfusion and/or skeletal muscle atrophy and dysfunction may be significant mediators of a low _ VO 2 , particularly in hospitalized patients who reported higher leg discomfort for a given _ VO 2 . This hypothesis is supported by the observed reduction in oxygen pulse in the context of a preserved ejection fraction in hospitalized patients, increasing evidence of COVID-19-related microvascular injury in various organs and the effects of critical illness on muscle wasting (15) . Furthermore, compromised oxygen use at the peripheral muscles may exacerbate symptom perception, which may result in the early attainment of intolerable breathlessness and premature termination of exercise (16, 17) . Physical deconditioning and concurrent comorbid conditions likely also contributed to the reduction in peak _ VO 2 in hospitalized patients. Finally, poor cardiorespiratory fitness in hospitalized patients may have preceded SARS-CoV-2 infection (18) .

We provide the first report of CI in patients recovering from COVID-19. The lower peak _ VO 2 and heart rate in hospitalized versus nonhospitalized patients in the setting of a comparable peak respiratory quotient suggests that CI contributed to exercise limitation. The source of CI is unknown but may be due to the high prevalence of comorbid conditions in hospitalized patients, or it may be secondary to patients becoming breathless and terminating exercise before achieving a maximal heart rate response. Limitations of this study include a small sample size, lack of premorbid baseline information, and absence of matched control groups. Therefore, we cannot be certain if the physiologic abnormalities in our patients preceded or followed SARS-CoV-2 infection. Given the important differences in the demographic and clinical makeup of our study groups, we could not adequately assess the confounding effects that preexisting comorbidities could have on our observations. Finally, we caution against the generalizability of our results given the small sample size and use of Canadian reference values (8) (9) (10) .

In conclusion, we demonstrate mild impairments in lung volumes and gas exchange and a diminished functional capacity 3-4 months after discharge from hospital with SARS-CoV-2 infection, which occurred in the presence of a preserved left ventricular ejection fraction. Investigations into the effects of COVID-19 on peripheral muscle structure, perfusion, and function are warranted. Additional studies are required to understand the mechanisms of breathlessness after SARS-CoV-2 infection, particularly in patients not requiring hospitalization.

Author disclosures are available with the text of this letter at www.atsjournals.org.

Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19

Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia

Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome?

lung function and CT findings three months after hospital admission for COVID-19

Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19

Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge

Effect of resveratrol on exercise capacity: a randomized placebo-controlled crossover pilot study

LHCE study investigators. Canadian prediction equations of spirometric lung function for Caucasian adults 20 to 90 years of age: results from the Canadian Obstructive Lung Disease (COLD) study and the Lung Health Canadian Environment (LHCE) study

Reference values of pulmonary function tests for Canadian Caucasians

CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. Normative peak cardiopulmonary exercise test responses in Canadian adults aged $40 years

Chronotropic incompetence as a predictor of death among patients with normal electrograms taking beta blockers (metoprolol or atenolol)

Common mechanisms of dyspnea in chronic interstitial and obstructive lung disorders

Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis

Pulmonary function and exercise capacity in survivors of severe acute respiratory syndrome

Acute skeletal muscle wasting in critical illness

Group III and IV muscle afferents contribute to ventilatory and cardiovascular response to rhythmic exercise in humans

Influences of spinal anesthesia on exercise tolerance in patients with chronic obstructive pulmonary disease

Inverse relationship of maximal exercise capacity to hospitalization secondary to coronavirus disease 2019

Copyright © 2021 by the American Thoracic Society Tissue Plasminogen Activator in Critically Ill Adults with COVID-19

Hypercoagulability may be a key factor leading to multiorgan failure and death in critically ill patients with coronavirus disease

The primary efficacy endpoint was change in the ratio of partial pressure of arterial oxygen to fraction of inspired oxygen (Pa O 2 :FI O 2 ) before and after tPA administration. Secondary efficacy endpoints were the proportion of patients who required therapies for refractory hypoxemia (prone position, neuromuscular blockade, or inhaled pulmonary vasodilators), the proportion of patients with an increase in the Pa O 2 :FI O 2 ratio >50% after tPA administration, and the change in the vasoactive-inotropic score (VIS) in the first 24 hours after tPA administration (10-12)

The authors thank Lori Ann Smith-Seguin, Nathalie Duffy, and Mylene Michaud for performing all pulmonary function and cycle cardiopulmonary exercise test procedures. They also thank Isabelle Seguin-Latreille, Danielle Tardiff, Laurie Bretzlaff, Wendy Fusee, Bashour Yazji, and Caroline Tessier for their assistance in coordinating the study.